HHS Awards $191K Psoriasis Grant to Biotherapeutics
The U.S. Department of Health and Human Services has awarded Biotherapeutics, Inc., based in Blacksburg, Va., a $191,331 grant, confirming the Biotherapeutics Inc psoriasis grant Blacksburg award supporting research into a first-in-class psoriasis treatment.
What the Biotherapeutics Inc Psoriasis Grant Blacksburg Actually Funds
The funding supports research into therapies for psoriasis, a skin disease that affects millions of Americans. The grant notice did not specify the funding mechanism, awarding HHS division, or project timeline beyond the topline award amount and disease focus.
Why a Rural Virginia Biotech Company Drew Congressional Attention
U.S. Rep. Morgan Griffith, R-Va., issued a statement in response to the grant notice. Griffith represents Virginia’s Ninth Congressional District, which includes Blacksburg and the broader New River Valley region, and has a pattern of publicly highlighting federal research grants awarded to companies and institutions within his district.
Griffith’s Statement on the Biotherapeutics Inc Psoriasis Grant Blacksburg Award
“Psoriasis is a skin disease that affects millions of Americans,” Griffith said. “This grant for more than $191,000 helps Biotherapeutics, Inc. study a first-in-class treatment for psoriasis.” His statement frames the grant specifically around advancing a treatment approach not yet represented among existing psoriasis therapies.
Griffith’s Broader Role in Federal Health Policy
As a member of the House Committee on Energy and Commerce, Griffith serves as chairman of the Health Subcommittee, a position that gives him direct oversight relevance to HHS research funding decisions even as his statement here functions as constituent-facing recognition rather than a policy announcement.
How This Fits Biotherapeutics, Inc.’s Recent HHS Funding History
This psoriasis grant follows a separate $500,000 HHS grant the same Blacksburg-based company recently received to support research into therapies for Alzheimer’s disease. Griffith issued a similar statement on that earlier award, citing public figures who have spoken about their own Alzheimer’s diagnoses as context for the importance of continued federal investment in new treatments.
Why Multiple Grants to the Same Company Matters
Receiving two separate HHS grants in a short span, one for psoriasis and one for Alzheimer’s disease, suggests Biotherapeutics, Inc. maintains active research programs across more than one therapeutic area simultaneously, though the source material does not indicate whether these represent the company’s only current federal funding or part of a broader portfolio.
Why Small Biotech Firms Often Rely on This Type of Federal Funding
Grants of this scale are consistent with early-stage research funding mechanisms federal agencies like HHS commonly use to support smaller, privately held biotech companies pursuing novel treatment candidates before they reach the larger capital investment typically needed for later-stage clinical trials. For a company based outside major biotech hubs, this kind of federal research funding can play an outsized role in sustaining early discovery work that might otherwise struggle to attract venture capital at the same stage of development.
What This Biotherapeutics Inc Psoriasis Grant Blacksburg Award Means Going Forward
With limited detail available about the specific research methodology or expected timeline, the practical significance of this $191,331 award will depend on how Biotherapeutics, Inc. applies the funding toward advancing its stated first-in-class psoriasis treatment candidate. Given the company’s concurrent Alzheimer’s disease research funded by a separate, larger HHS grant, Biotherapeutics, Inc. appears to be pursuing federally supported research across at least two distinct disease areas.
What to Watch Going Forward
As Biotherapeutics, Inc. continues its research, observers in the New River Valley region and the broader psoriasis research community may watch for further updates on the company’s progress, since the source material provided here offers only the initial grant announcement rather than ongoing research findings. Given Griffith’s demonstrated pattern of publicizing HHS awards to companies in his district, this Biotherapeutics Inc psoriasis grant Blacksburg award is likely one of several such federal research funding announcements the congressman may continue to highlight from institutions and companies across southwestern Virginia.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed
